Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.01
-0.00 (-6.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-7.8M · quality 33.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10209.2%
↓Gross Margin
59.4%
↑Debt/Equity
20.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+38.5%
FCF CAGR
—
FCF margin
-16.4%
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.4M · net income $-32.1M · FCF $-4.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.4M | $29.4M | $24.8M | $20.1M | $11.1M |
| Net Income | $-32.1M | $-32.1M | $-13.7M | $-12.1M | $-15.0M |
| EBITDA | $-28.9M | $-28.9M | $-10.4M | $-9.3M | $-13.0M |
| EPS | -0.09 | -0.09 | -0.04 | -0.04 | -0.06 |
| Gross Margin | 59.4% | 59.4% | 50.8% | 46.3% | 47.8% |
| Operating Margin | -39.8% | -39.8% | -54.8% | -63.6% | -139.0% |
| Net Margin | -109.0% | -109.0% | -55.3% | -60.4% | -135.9% |
| Balance Sheet | |||||
| Debt/Equity | 20.82 | 20.82 | 0.16 | 0.12 | 0.09 |
| Current Ratio | 0.67 | 0.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.8M | $-4.8M | $-7.8M | $-10.0M | $-12.8M |
| Returns | |||||
| ROE | -10209.2% | -10209.2% | -46.1% | -29.2% | -35.2% |
| Valuation | |||||
| P/B | 17.96 | 17.96 | 0.50 | 0.59 | 2.18 |
| Growth & Yield | |||||
| Revenue Growth | 18.4% | 18.4% | 23.7% | 81.3% | — |
| EPS Growth | -118.2% | -118.2% | 2.0% | 34.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.09
Residual
-42.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.